---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096139"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:37:58.962633+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M

## Summary
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.
- Cash, equivalents, restricted cash and investments totaled $81.4M as of June 30, 2024.
- R&D expenses $14.0M, G&A $3.3M for Q2 2024.
- Phase 2 EFZO-CONNECT for SSc-ILD enrolling; interim data expected Q2 2025.
- Appointed Jayant Aphale VP Technical Operations; research agreement with Stanford for anti-NRP2 in GBM.

## SEC filing metadata
- accession: 0000950170-24-096139
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/0000950170-24-096139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/atyr-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096139
- JSON: https://secwatch.observer/filing/0000950170-24-096139.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.